Publicacións nas que colabora con Ainara Elorza (12)

2024

  1. A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 8, pp. 821-833

  2. Combination of granulocyte–monocyte apheresis and ustekinumab: Multicentre and retrospective study

    Gastroenterologia y Hepatologia

  3. Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial

    Digestive Diseases

  4. Environmental Exposure to Trace Elements and Heavy Metals Preceding the Clinical Onset of Inflammatory Bowel Disease

    Crohn's and Colitis 360, Vol. 6, Núm. 1

  5. Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 750-758

  6. Prophylactic versus endoscopy-driven treatment of crohn's postoperative recurrence: A retrospective, multicentric, european study [porcse study]

    Journal of Crohn's and Colitis, Vol. 18, Núm. 8, pp. 1202-1214

  7. Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study

    Journal of Clinical Medicine, Vol. 13, Núm. 2

2023

  1. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

2022

  1. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  2. The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study

    Journal of Crohn's & colitis, Vol. 16, Núm. 11, pp. 1676-1686

2020

  1. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn’s disease

    United European Gastroenterology Journal, Vol. 8, Núm. 9, pp. 1056-1066

  2. Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease

    Alimentary Pharmacology and Therapeutics, Vol. 51, Núm. 9, pp. 870-879